Coronado, Pluvio J.Mendoza, NicolásGonzález, Silvia P.Sánchez-Méndez, SoniaPresa, JesúsJurado, Ana R.de la Viuda, EstherQuereda, FranciscoFasero, María2026-09-282026-09-282026-06Coronado, P J, Mendoza, N, González, S P, Sánchez-Méndez, S, Presa, J, Jurado, A R, de la Viuda, E, Quereda, F & Fasero, M 2026, 'Prevalence of vasomotor symptoms and the associated risk factors : the “Mi Menopausia” app study', Maturitas, vol. 209, 108958. https://doi.org/10.1016/j.maturitas.2026.1089580378-5122https://hdl.handle.net/10641/8310Publisher Copyright: © 2026 The AuthorsObjetivo: Evaluar la prevalencia de síntomas vasomotores (SVM) y sus factores de riesgo sociodemográficos, de estilo de vida y médicos asociados, así como su impacto en la calidad de vida relacionada con la salud (CVRS) en mujeres españolas peri- y posmenopáusicas usuarias de la app Mi Menopausia. Diseño del estudio: Muestra de conveniencia transversal de 13.956 mujeres registradas en la app Mi Menopausia (junio 2021–noviembre 2025). Se incluyeron 11.378 mujeres en el análisis final tras excluir datos incorrectos o incompletos, o antecedentes de cáncer. Principales medidas de resultado: SVM moderados a graves (SVM-MS), definidos como ≥7 sofocos/día con sudoración o intensidad ≥3/5. Resultados: Del total de 11.378 mujeres de la muestra final, el 48,4% eran perimenopáusicas y el 51,6% posmenopáusicas. La prevalencia de SVM fue del 77,4% y de SVM-MS del 63,9%. Los SVM-MS se asociaron de forma independiente con obesidad (odds ratio [OR] 1,27; intervalo de confianza [IC] 95% 1,12–1,45), tabaquismo (OR 1,26; IC95% 1,12–1,42), consumo de alcohol (OR 1,20; IC95% 1,06–1,34) y antecedente de ooforectomía bilateral (OR 1,38; IC95% 1,03–1,84). La educación universitaria (OR 0,71; IC95% 0,65–0,77), estar empleada (OR 0,85; IC95% 0,76–0,96) y mantener relaciones sexuales (OR 0,87; IC95% 0,78–0,97) se asociaron de forma independiente con menores probabilidades de SVM-MS. Los síntomas menopáusicos vinculados a SVM-MS fueron irritabilidad (OR 1,65; IC95% 1,12–2,41), insomnio (OR 2,23; IC95% 1,52–3,27), sentirse mayor (OR 1,93; IC95% 1,32–2,83) y sequedad vaginal (OR 10,66; IC95% 2,71–41,87). Las fracturas óseas (OR 1,16; IC95% 1,02–1,33), la depresión/ansiedad (OR 1,37; IC95% 1,24–1,50), la cardiopatía (OR 1,51; IC95% 1,12–2,02) y la neumopatía (OR 2,30; IC95% 1,28–4,13) fueron más frecuentes en mujeres con SVM-MS. Las mujeres con SVM-MS presentaron menor CVRS medida mediante la escala Cervantes SF. Solo el 17% de las mujeres con SVM recibían tratamiento; el 9,2% usaba terapia hormonal. Conclusión: Los SVM, especialmente los SVM-MS, se asociaron con una menor CVRS y con múltiples factores de riesgo, lo que respalda la necesidad clínica de intervenciones dirigidas en mujeres menopáusicas. [Traducción automática al español; idioma original: inglés.]Objective: To assess the prevalence of vasomotor symptoms (VMS) and their associated sociodemographic, lifestyle, and medical risk factors, as well as their impact on health-related quality of life (HRQOL) in peri- and postmenopausal Spanish women using the Mi Menopausia app. Study design: Cross-sectional convenience sample of 13,956 women registered with the Mi Menopausia app (June 2021–November 2025). A total of 11,378 women were included in the final analysis after exclusions for incorrect or incomplete data, or cancer history. Main outcome measures: Moderate to severe VMS (MS-VMS), defined as ≥7 hot flashes/day with sweating or intensity ≥3/5. Results: Of the total of 11,378 women in the final sample, 48.4% were peri- and 51.6% postmenopausal. The prevalence of VMS was 77.4% and MS-VMS 63.9%. MS-VMS were independently associated with obesity (odds ratio [OR] 1.27; 95% confidence interval [CI] 1.12–1.45), smoking (OR 1.26; 95%CI 1.12–1.42), alcohol intake (OR 1.20; 95%CI 1.06–1.34), and a history of bilateral oophorectomy (OR 1.38; 95%CI 1.03–1.84). University education (OR 0.71; 95%CI 0.65–0.77), being employed (OR 0.85; 95%CI 0.76–0.96) and having sexual intercourse (OR 0.87; 95%CI 0.78–0.97) were independently associated with lower odds of MS-VMS. The menopausal symptoms linked to MS-VMS were irritability (OR 1.65; 95%CI 1.12–2.41), insomnia (OR 2.23; 95%CI 1.52–3.27), feeling older (OR 1.93; 95%CI 1.32–2.83) and vaginal dryness (OR 10.66; 95%CI 2.71–41.87). Bone fractures (OR 1.16; 95%CI 1.02–1.33), depression/anxiety (OR 1.37; 95%CI 1.24–1.50), cardiopathy (OR 1.51; 95%CI 1.12–2.02) and pneumopathy (OR 2.30; 95%CI 1.28–4.13) were more common in women with MS-VMS. Women with MS-VMS had lower HRQOL as measured by the Cervantes SF scale. Only 17% of women with VMS were treated; 9.2% used hormone therapy. Conclusion: VMS, especially MS-VMS, were associated with reduced HRQOL and with multiple risk factors, supporting the clinical need for targeted interventions in menopausal women.91970058enghttp://creativecommons.org/licenses/by-nc-nd/4.0/HRQOLHot flashesMenopausal symptomsMenopauseNight sweatsQuality of lifeVasomotor symptomsGeneral Biochemistry, Genetics and Molecular BiologyObstetrics and GynecologySDG 3 - Good Health and Well-beingJournal ArticleYesjournal articleopen access10.1016/j.maturitas.2026.108958https://www.scopus.com/pages/publications/105037474049https://www.scopus.com/pages/publications/105037474049#tab=citedBy